Lessina crossover to AG200-15

Lessina crossover to AG200-15 refers to a specific clinical trial regimen where participants transition from the daily oral contraceptive Lessina to the weekly transdermal contraceptive patch AG200-15 (marketed as Twirla). Lessina is a low-dose combination oral contraceptive containing 0.02 mg ethinyl estradiol and 0.1 mg levonorgestrel. AG200-15 is a transdermal patch developed by Agile Therapeutics that delivers the same active ingredients—ethinyl estradiol and levonorgestrel—using proprietary Skinfusion technology. The regimen is designed to prevent pregnancy by suppressing ovulation through the activation of estrogen and progesterone receptors, which provides negative feedback to the hypothalamus and pituitary gland, inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This crossover design was utilized in Phase 3 studies to evaluate the safety, efficacy, and patient experience when switching from a daily pill to a weekly patch.

Brand names

TwirlaLessina

Other names

ethinyl estradiol + levonorgestrel